Larvol Delta - AB101-OutpatientAdministered-NonGenetically-Modified-NK-Cells-in-Combination-with-Rituximab-Generate-Robust-Efficacy-Responses-Comparable-with-Autologous-CAR-T-in-34-Patients-with-Rheumatologic-Diseases

AlloNK (AB-101) - Artiva Biotherapeutics

Rituxan (rituximab) - Roche

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1896652&mode=presInfo

Guillermo J. Valenzuela, n/a

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next